Latest Human Genome Sciences Inc. Stories
A drug for lupus, produced by Human Genome Sciences Inc, is set to get clearance from health regulators, bringing patients the first approved treatment in more than 50 years, and potentially bringing heavy revenue to the company.
HONG KONG, March 1 /PRNewswire/ - Today, www.WorldStreetFundamentals.com released its industry report highlighting Dendreon Corp. (NASDAQ: DNDN) and Human Genome Sciences, Inc. (NASDAQ: HGSI).
BOSTON, Nov. 15, 2010 /PRNewswire/ -- The Securities and Exchange Commission and the United States Department of Justice have filed civil and criminal complaints alleging that the defendant in those cases (Yves M.
VANCOUVER, Canada, Sept. 3 /PRNewswire-Asia/ -- Insiderslab.com issues new research reports that highlight large insider trades found in for Atmel, Baker Hughes, Amgen, First Solar, Human Genome Sciences, & Aruba.
- A hairdresser.